» Articles » PMID: 39173878

Early Thrombus Formation is Required for Eccentric and Heterogeneous Neointimal Hyperplasia Under Disturbed Flow

Overview
Publisher Elsevier
Specialty Hematology
Date 2024 Aug 22
PMID 39173878
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anticoagulation and antiplatelet therapy effectively inhibit neointimal hyperplasia (NIH) in both arterial and venous systems but not in arteriovenous fistulae (AVF). The main site of AVF failure is the juxta-anastomotic area that is characterized by disturbed flow compared with laminar flow in the arterial inflow and the venous outflow.

Objectives: We hypothesized that early thrombus formation is required for eccentric and heterogeneous NIH in the presence of disturbed flow.

Methods: Needle puncture and sutured AVF were created in C57BL/6 mice, in PF4-Cre × mT/mG reporter mice, and in Wistar rats. Human AVF samples were second-stage basilic vein transpositions. The tissues were examined by histology, immunofluorescence, immunohistochemistry, and en face staining.

Results: In the presence of disturbed flow, both mouse and human AVF showed eccentric and heterogeneous NIH. Maladapted vein wall was characterized by eccentric and heterogeneous neointima that was composed of a different abundance of thrombus and smooth muscle cells. PF4-cre × mT/mG reporter mice AVF showed that green fluorescent protein-labeled platelets deposit on the wall directly facing the fistula exit with endothelial cell loss and continue to accumulate in the presence of disturbed flow. Neither disturbed flow with limited endothelial cell loss nor nondisturbed flow induced heterogeneous neointima in different animal models.

Conclusion: Early thrombus contributes to late heterogeneous NIH in the presence of disturbed flow. Disturbed flow, large area of endothelial cell loss, and thrombus formation are critical to form eccentric and heterogeneous NIH. Categorization of adapted or maladapted walls may be helpful for therapy targeting heterogeneous NIH.

References
1.
Bai H, Wu H, Zhang L, Sun P, Liu Y, Xie B . Adventitial injection of HA/SA hydrogel loaded with PLGA rapamycin nanoparticle inhibits neointimal hyperplasia in a rat aortic wire injury model. Drug Deliv Transl Res. 2022; 12(12):2950-2959. DOI: 10.1007/s13346-022-01158-x. View

2.
Lok C, Moist L . More than reducing early fistula thrombosis is required: lessons from the Dialysis Access Consortium clopidogrel fistula study. Am J Kidney Dis. 2008; 52(5):834-8. DOI: 10.1053/j.ajkd.2008.09.005. View

3.
Dinc R . A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy. Transl Clin Pharmacol. 2024; 31(4):191-201. PMC: 10772059. DOI: 10.12793/tcp.2023.31.e18. View

4.
Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, OShaughnessy C . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14):1315-23. DOI: 10.1056/NEJMoa035071. View

5.
Hoglund V, Dong X, Majesky M . Neointima formation: a local affair. Arterioscler Thromb Vasc Biol. 2010; 30(10):1877-9. PMC: 3049730. DOI: 10.1161/ATVBAHA.110.211433. View